Back to Search
Start Over
How we treat cytomegalovirus in hematopoietic cell transplant recipients.
- Source :
-
Blood [Blood] 2009 Jun 04; Vol. 113 (23), pp. 5711-9. Date of Electronic Publication: 2009 Mar 18. - Publication Year :
- 2009
-
Abstract
- Cytomegalovirus (CMV) continues to cause major complications after hematopoietic cell transplantation (HCT). Over the past decade, most centers have adopted preemptive antiviral treatment or prophylaxis strategies to prevent CMV disease. Both strategies are effective but also have shortcomings with presently available drugs. Here, we review aspects of CMV treatment and prevention in HCT recipients, including currently used drugs and diagnostics, ways to optimize preemptive therapy strategies with quantitative polymerase chain reaction assays, the use of prophylaxis, management of CMV disease caused by wild-type or drug-resistant strains, and future strategies.
- Subjects :
- Animals
Antiviral Agents therapeutic use
Cytomegalovirus Infections blood
Cytomegalovirus Infections diagnosis
Drug Resistance, Viral drug effects
Humans
Risk Factors
Cytomegalovirus Infections drug therapy
Cytomegalovirus Infections prevention & control
Hematopoietic Stem Cell Transplantation
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 113
- Issue :
- 23
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Academic Journal
- Accession number :
- 19299333
- Full Text :
- https://doi.org/10.1182/blood-2008-10-143560